Overview
Collaboration is an integral part of our corporate strategy - working together to execute common goals - by sharing intellectual endeavour, knowledge, creativity, learning and building consensus.
Syntaxin’s management team is experienced in building strong relationships with pharmaceutical and academic partners to generate value creating alliances and access development and commercial resources on a global basis.
Syntaxin will seek to deliver value via development of its internal programmes and by entering into high-value alliances at an appropriate time during the drug development cycle. In addition, Syntaxin will seek to exploit its unique technology platform by forging collaborative programmes.
Partnering Contact
Nigel Clark, Chief Business Officer
Email: partnering@syntaxin.com